Form 4: Bicara Therapeutics CFO Sells Shares in Planned Trade

Bicara Therapeutics CFO Ivan Hyep executed a pre-planned sale of 9,200 common shares following the exercise of stock options.

Summary

• Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc. (BCAX), reported transactions on December 22, 2025.
• Hyep exercised stock options to acquire 9,200 shares of common stock at an exercise price of $3.7898 per share.
• Concurrently, 9,200 shares of common stock were sold at a weighted average price of $18.3143 per share.
• The sale price ranged from $18.15 to $18.45 across multiple transactions.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on February 13, 2025.
• Following these transactions, Hyep directly beneficially owns 145,355 shares of common stock and 88,984 stock options.
• The underlying options vest in sixteen equal quarterly installments, commencing August 8, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it involves an executive selling shares, the transaction was pre-planned under a Rule 10b5-1 plan, which typically mitigates negative investor perception as it's for personal financial management rather than a reaction to company-specific news.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and systematic approach to managing equity compensation rather than a reactive sale.
• The significant difference between the option exercise price ($3.7898) and the sale price ($18.3143) demonstrates a substantial gain for the executive from their equity compensation.

Negatives

• An executive selling shares, even under a pre-planned arrangement, can sometimes be perceived negatively by investors as it reduces their direct equity stake in the company.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Industry Context

This insider transaction report is specific to Bicara Therapeutics and its Chief Financial Officer, Ivan Hyep. It reflects an individual's management of personal equity compensation and does not directly indicate broader industry trends or competitive dynamics within the biotechnology sector.

Stakeholder Impact

• Shareholders: May observe the CFO reducing direct share ownership, though the pre-planned nature under Rule 10b5-1 suggests it is for personal financial management rather than a signal about company prospects. The significant gain realized by the CFO could be viewed positively as a reward for executive performance.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Ivan Hyep, CFO, insider trading, Form 4, stock options, share sale, 10b5-1 plan, beneficial ownership